| Thu, 23 May 2019 15:40:54: | GSK tweaks ethics-based rep compensation rules to recruit and retain talent
|
| Thu, 23 May 2019 14:31:14: | Want bang for your buck? Don't look to Sarepta's pricey DMD therapy Exondys, ICER says
|
| Thu, 23 May 2019 13:31:11: | Daiichi Sankyo looking to sell OTC business for $900M? 'Not correct,' says company
|
| Thu, 23 May 2019 13:22:14: | J&J's Invokana closes in on badly needed kidney disease nod with FDA 'priority' boost
|
| Thu, 23 May 2019 13:11:16: | Novartis CEO says Zolgensma won't cost anywhere near the $4M to $5M once quoted
|
| Thu, 23 May 2019 12:04:53: | Boehringer Ingelheim plans 3-year, $84M expansion in Mexico
|
| Thu, 23 May 2019 02:03:04: | Dendreon commits to prostate cancer vaccine Provenge with new lease for manufacturing site
|
| Wed, 22 May 2019 14:49:17: | Array's ‘extremely compelling’ new colon cancer data spark blockbuster talk
|
| Wed, 22 May 2019 14:01:36: | Lilly to insulin pricing critics: Check out our 50%-off Humalog copy instead
|
| Wed, 22 May 2019 13:54:13: | Daiichi Sankyo comes up far short of promised avian flu vaccine production
|
| Wed, 22 May 2019 13:24:21: | J&J's good news, bad news day in talc court yields win in South Carolina, $25M loss in New York
|
| Wed, 22 May 2019 13:19:03: | GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China
|
| Tue, 21 May 2019 15:30:43: | Baltimore sues J&J for spinning up a 'sham' Zytiga patent to fend off generics
|
| Tue, 21 May 2019 14:43:33: | WuXi to build dedicated vaccine facility, but who's the client?
|
| Tue, 21 May 2019 14:00:26: | Supreme Court puts Merck's FDA preemption argument up for another review
|
| Tue, 21 May 2019 13:41:13: | See you in court: Mallinckrodt takes on feds to fight $600M in back Acthar rebates
|
| Tue, 21 May 2019 13:30:28: | Seattle Genetics taps pharma oncology veteran as first-ever chief commercial officer
|
| Tue, 21 May 2019 13:04:48: | Merck's powerhouse Keytruda whiffs breast cancer trial, delaying hopes for new use
|
| Tue, 21 May 2019 12:37:25: | Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies
|
| Mon, 20 May 2019 14:31:49: | Hurting for revenue, Mylan shells out $130M for basket of Aspen drugs
|
| Mon, 20 May 2019 14:21:36: | AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst
|
| Mon, 20 May 2019 14:18:02: | CSL Behring poaches top manufacturing executive from struggling Biogen
|
| Mon, 20 May 2019 13:28:46: | 'Cornucopia' of biopharma innovation blurs drug launch forecasts, analyst laments
|
| Mon, 20 May 2019 12:40:20: | J&J targets different audiences with Xarelto TV commercial trio
|
| Mon, 20 May 2019 12:14:32: | AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis
|
